Lattice_grid_med
Powered by LatticeGrid

Search Enter term and hit return. Use '*' for as a wildcard.

Publication Listing for the MeSH term MORTALITY. Found 9 abstracts

Chang BL, Hughes L, Chen DY, Gross L, Ruth K, Giri VN. Validation of association of genetic variants at 10q with prostate-specific antigen (PSA) levels in men at high risk for prostate cancer. BJU international. 2014 May;113(5B):E150-E156.   PMCID: PMC 3830710
Kim SP, Karnes RJ, Nguyen PL, Ziegenfuss JY, Thompson RH, Han LC, Shah ND, Smaldone MC, Gross CP, Frank I, Weight CJ, Beebe TJ, Tilburt JC. A national survey of radiation oncologists and urologists on recommendations of prostate-specific antigen screening for prostate cancer. BJU international. 2014 May;113(5B):E106-E111.
Bilimoria KY, Palis B, Stewart AK, Bentrem DJ, Freel AC, Sigurdson ER, Talamonti MS, Ko CY. Impact of tumor location on nodal evaluation for colon cancer. Diseases of the Colon & Rectum. 2008 Feb;51(2):154-61.
Alcantara P, Hanlon A, Buyyounouski MK, Horwitz EM, Pollack A. Prostate-specific antigen nadir within 12 months of prostate cancer radiotherapy predicts metastasis and death. Cancer. 2007 Jan;109(1):41-7.
Cui XH, Dai Q, Tseng M, Shu XO, Gao YT, Zheng W. Dietary patterns and breast cancer risk in the Shanghai breast cancer study. Cancer Epidemiology Biomarkers & Prevention. 2007 Jul;16(7):1443-8.
Hess LM, Barakat R, Tian C, Ozols RF, Alberts DS. Weight change during chemotherapy as a potential prognostic factor for stage III epithelial ovarian carcinoma: A Gynecologic Oncology Group study. Gynecologic Oncology. 2007 Nov;107(2):260-5.
Katz SJ, Hofer TP, Hawley S, Lantz PM, Janz NK, Schwartz K, Liu L, Deapen D, Morrow M. Patterns and correlates of patient referral to surgeons for treatment of breast cancer. Journal of Clinical Oncology. 2007 Jan;25(3):271-6.
Welzel TM, Katki HA, Sakoda LC, Evans AA, London WT, Chen G, O'Broin S, Shen FM, Lin WY, McGlynn KA. Blood folate levels and risk of liver damage and hepatocellular carcinoma in a prospective high-risk cohort. Cancer Epidemiology Biomarkers & Prevention. 2007 Jun;16(6):1279-82.
Valicenti RK, DeSilvio M, Hanks GE, Porter A, Brereton H, Rosenthal SA, Shipley WU, Sandler HM, Haile RW, Thomas DC, McGuire V, Felberg A, John EM, Milne RL, Hopper JL, Jenkins MA, Levine AJ, Daly MM, Buys SS, Senie RT, Andrulis IL, Knight JA, Godwin AK, Southey M, McCredie MR, Giles GG, Andrews L, Tucker K, Miron A, Apicella C, Tesoriero A, Bane A, Pike MC, Whittemore AS. Posttreatment prostatic-specific antigen doubling time as a surrogate endpoint for prostate cancer-specific survival: An analysis of radiation therapy oncology group protocol 92-02 BRCA1 and BRCA2 mutation carriers, oral contraceptive use, and breast cancer before age 50. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS LA English DT Article DE prostate cancer; prostate-specific antigen doubling time; mortality; surrogate endpoint. 2006 Oct;15(10):1863-70.
The above publications are sorted by year, faculty last name, and first author. Click on any highlighted author listed to find all publications attributed to that individual. Click on the publication title to see the abstract. First authors who are faculty are highlighted like this. Last authors who are faculty are highlighted like this. Other authors who are faculty are highlighted like this.

MeSH cloud from publications including the MeSH term MORTALITY

MORTALITY POSTMENOPAUSAL WOMEN screening CARCINOMA prostate-specific antigen Urology & Nephrology FOLLOW-UP prostate cancer RISK TRIAL PCR COHORT but did not meet all of Prentice's significantly associated with CSS OVERWEIGHT NONCARRIERS BIOCHEMICAL FAILURE METASTASES DISTANT the randomized treatment prostate-specific antigen nadir MICROBIOLOGIC ASSAY HOSPITAL VOLUME RESPONSE RATES PACLITAXEL RESECTION PROGNOSIS OVARIAN-CANCER RECOMMENDATIONS chemotherapy RISK AB (Purpose:) under bar We evaluated whether posttreatment CONSERVING SURGERY Gleason score and PSA stage-all of Prentice's requirements were not GUIDELINE nodes BREAST-CANCER WOMEN on Radiation Therapy Oncology Group Protocol 92-02 From June 1992 to time to PSADT (assuming first-order kinetics for a minimum of 3 rising REGISTRY genetics SUSCEPTIBILITY indicating that the effect of PSADT on CSS was not independent of met of prostate cancer is not fully explained by PSADT (c) 2006 Elsevier SERUM CANCER INCIDENCE GENE colon neoplasms RADICAL PROSTATECTOMY Inc SERVICES TASK-FORCE TANDEM MASS-SPECTROMETRY FIBROSIS survival HAIMEN-CITY colectomy (Results: ) under bar After a median follow-up time of 59 years PSA measurements) and cancer-specific survival (CSS) FAILURE MINIMUM NUMBER BEAM RADIATION-THERAPY BMI GENOME-WIDE ASSOCIATION body weight prostatic neoplasms COLORECTAL-CANCER 3D conformal CARBOPLATIN UNITED-STATES HORMONES 514 men with localized prostate cancer measurements in a cohort of 1 SURGERY REPRODUCIBILITY RECURRENCE (T2c-4 and PSA level < 150 ng distant metastasis DEATH we tested if PSADT was prognostic and Cox proportional hazards model outcomes (Conclusions) under bar Prostatic specific antigen doubling time is PHYSICAL-ACTIVITY DOSE-ESCALATION LOCAL THERAPY (P-Cox = 04) The significant posttreatment PSADTs were also National Cancer Data Base EPIDEMIOLOGY CARRIERS staging radiotherapy HISTORY family history cause-specific mortality independent of randomized treatment in this cohort The endpoints were OXIDATIVE STRESS survey ovarian cancer significant predictors of CSS (P-Cox < 0001) After adjusting for T BODY-MASS INDEX PSA THRESHOLD-MODEL PROGNOSTIC VALUE VOLUME (Methods and Materials: ) under bar We analyzed posttreatment PSA CHINA or in combination with 24 65-70 Gy of radiation therapy (n = 761) SURROGATE END-POINT PSADT < 6 months (pc < 0001) 0002)-PSADT < 9 months (P-Cox < LYMPH-NODES and PSADT < 12 months (P-Cox < 0001) but not for PSADT < 3 0001) FOOD-FREQUENCY QUESTIONNAIRE randomized treatment was a significant predictor for CSS (p(Cox) = CARE months of adjuvant androgen deprivation (n = 753) Using an adjusted SURVIVAL men were randomized to neoadjuvant androgen deprivation and April 1995 VALIDITY prostatic-specific antigen doubling time (PSADT) was predictive of SOCIETY lymph prostate cancer mortality by testing the Prentice requirements for a DISEASE-FREE SURVIVAL OBESITY treated and monitored prospectively mL) LOCI surgery CONSUMPTION the risk of dying requirements for a surrogate endpoint of CSS Thus surrogate endpoint OUTCOMES
Last updated on Monday, May 04, 2020